Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tesis Labs

Explore full profile

A unique integrated medical platform that is revolutionizing targeted genetic sequencing

Phoenix, United StatesFounded 2019Biotech & Life Sciences
Valuation $500M–1B Last recorded · 2021
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Tesis Labs and the history behind them.

About Tesis Labs

Tesis Biosciences is a cutting-edge biotech startup that operates in the pharmaceutical and medical device industries. The company specializes in targeted genetic sequencing and comprehensive genetic data collection, which are advanced techniques used to analyze and understand the genetic makeup of individuals. This information is crucial for the development of personalized treatments and therapies, particularly for chronic diseases.

Tesis Biosciences' primary clients are pharmaceutical and medical device companies. These companies rely on Tesis for genetic testing services and access to their extensive genetic database. This collaboration helps to de-risk drug development processes and accelerates the time it takes to bring new products to market.

In addition, Tesis partners with hospitals to provide high-complexity testing expertise and technology. This partnership enhances the quality and efficiency of patient care, as well as the timeliness of information flow. Physicians and large medical groups also benefit from Tesis' state-of-the-art genetic, pathology, and infectious disease testing systems, which enable them to design personalized, preventative care plans for their patients.

The company's business model revolves around providing these specialized services and access to its genetic database. Revenue is generated through service fees charged to pharmaceutical companies, medical device manufacturers, hospitals, and medical groups.

In summary, Tesis Biosciences is a revolutionary biotech company that leverages targeted genetic sequencing and data collection to improve drug development, disease management, and patient care.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Phoenix, United States
Employees
17
Open positions
None listed
Dealroom signal
83.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
SaaS
Client focus
b2b

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GROWTH EQUITY VC✓Equity / VC Oct 2021 $20M $520M Xcellerant 1 TLC —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Tesis Labs website traffic

Latest recorded traffic for Tesis Labs is 280 monthly website visits. Tesis Labs's team grew 54.5% over the past year.

Latest monthly visits280 1-year team growth+54.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
PhaseVUses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data Tel Aviv-Yafo, Israel Operational 71 $65M $200M
Wheeler BioBy bringing together biologics drug innovators, discovery CROs, and CDMOs accelerating the translation of therapeutic innovation to clinical impact Oklahoma City, United States Operational
Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases Graz, Austria Operational
Rubix strategiesA research and development company focusing on the gaps of product development toward effective patient outcomes through real-world evidence design and creating digital platforms for increasing patient diversity in Phase I/II clinical trials Lawrence, United States Operational
Sepax-techBetter Surface Chemistry for Better Separation Newark, United States Operational
ExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening Oxford, United Kingdom Operational
EleusisLeusis is a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design London, United Kingdom Acquired
NanoSyrinxA cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector Coventry, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Xcellerant 1 TLC
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Phoenix HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tesis Labs on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tesis Labs’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.